INTRATHECAL ADMINISTRATION OF I-131 RADIOLABELED MONOCLONAL-ANTIBODY AS A TREATMENT FOR NEOPLASTIC MENINGITIS

被引：53

作者：

MOSELEY, RP

DAVIES, AG

RICHARDSON, RB

ZALUTSKY, M

CARRELL, S

FABRE, J

SLACK, N

BULLIMORE, J

PIZER, B

PAPANASTASSIOU, V

KEMSHEAD, JT

COAKHAM, HB

LASHFORD, LS

机构：

[1] FRENCHAY HOSP, IMPERIAL CANC RES FUND, PAEDIAT & NEUROONCOL GRP, BRISTOL BS16 1LE, AVON, ENGLAND

[2] FRENCHAY HOSP, DEPT NEUROSURG, BRAIN TUMOUR RES LAB, BRISTOL BS16 1LE, AVON, ENGLAND

[3] FRENCHAY HOSP, DEPT NUCL MED, BRISTOL BS16 1LE, AVON, ENGLAND

[4] DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA

[5] LUDWIG INST CANC RES, CH-1066 EPALINGES, SWITZERLAND

[6] E GRINSTEAD MED RES TRUST, BLOND MCINDOE CTR MED RES, E GRINSTEAD RH19 3DZ, W SUSSEX, ENGLAND

[7] BRISTOL ROYAL INFIRM & GEN HOSP, BRISTOL BS2 8HW, AVON, ENGLAND

来源：

BRITISH JOURNAL OF CANCER | 1990年 / 62卷 / 04期

关键词：

D O I：

10.1038/bjc.1990.345

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fifteen patients with neoplastic meningitis received a single intrathecal injection of between 11 and 60mCi of a 131I radiolabelled monoclonal antibody (MoAb), chosen for its immunoreactivity to tumour. Major toxicity was manifest as nausea, vomiting and headache (7/15 patients), reversible bone marrow suppression (3/8 patients) and seizures (2/15 patients). Nine patients were evaluable for either a tumour or clinical response. Six of these demonstrated an event-free response that was maintained for periods of between 7 and 26 months. © Macmillan Press Ltd., 1990.

引用

页码：637 / 642

页数：6

共 34 条

[1] AGGI GLB, 1985, CANCER RES, V45, P3378
[2] BIOLOGICAL CHARACTERIZATION AND CLINICAL-APPLICATIONS OF A MONOCLONAL-ANTIBODY RECOGNIZING AN ANTIGEN RESTRICTED TO NEUROECTODERMAL TISSUES
ALLAN, PM
GARSON, JA
HARPER, EI
ASSER, U
COAKHAM, HB
BROWNELL, B
KEMSHEAD, JT
[J]. INTERNATIONAL JOURNAL OF CANCER, 1983, 31 (05) : 591 - 598
[3] AZZARELLI B, 1977, ARCH PATHOL LAB MED, V101, P203
[4] BOURDON MA, 1983, CANCER RES, V43, P2796
[5] MONOCLONAL-ANTIBODIES M340 AND UJ181.4 RECOGNIZE ANTIGENS ASSOCIATED WITH PRIMITIVE NEUROECTODERMAL TUMORS TISSUES
BOURNE, S
PEMBERTON, L
MOSELEY, R
LASHFORD, LS
COAKHAM, HB
KEMSHEAD, JT
[J]. HYBRIDOMA, 1989, 8 (04): : 415 - 426
[6] CARRASQUILLO JA, 1984, CANCER TREAT REP, V68, P317
[7] CARREL S, 1980, CANCER RES, V40, P2523
[8] CRANIAL IRRADIATION IN CHILDHOOD LYMPHOBLASTIC-LEUKEMIA - TIME FOR REAPPRAISAL
CHESSELLS, JM
[J]. BRITISH MEDICAL JOURNAL, 1985, 291 (6497) : 686 - 687
[9] GANGLIOSIDE GD2 SPECIFIC MONOCLONAL ANTIBODY-3F8 - A PHASE-I STUDY IN PATIENTS WITH NEUROBLASTOMA AND MALIGNANT-MELANOMA
CHEUNG, NKV
LAZARUS, H
MIRALDI, FD
ABRAMOWSKY, CR
KALLICK, S
SAARINEN, UM
SPITZER, T
STRANDJORD, SE
COCCIA, PF
BERGER, NA
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (09) : 1430 - 1440
[10] COURTENAYLUCK NS, 1986, CANCER RES, V46, P6489

← 1 2 3 4 →